Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals.
Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy.
The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers.
An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics.
Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development.
Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world.
About Alfa Cytology
Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Walsh Pure Supply & Demand
The July WASDE report was released this morning from the USDA. December corn made a high at 418 after the numbers came out, but faded the rest of the day, closing at 412 1/4. December corn has support at 409, 400, and 393; resistance is at 416 and 420. New Crop New crop ending stocks were 1.66 billion bushels (bb), less than the trade expectation at 1.722 bb. The stocks/use ratio is now 10.8%, a reduction of half a percent from last month's report. Old Crop Old crop ending stocks were reduced to 1.34 bb, compared to the trade estimate at 1.352 bb and the June estimate at 1.365 bb. As mentioned in my article on Wednesday, exports were raised by 100 million bushels (mb). Feed and residual use was cut 75 mb based on indicated disappearance in the June 30 th Grain Stocks report. Old crop stocks/use is 8.75%. Global Global new crop ending stocks were also reported less than expected at 272.1 million metric tons (mmt), which is 3.1 mmt less than June. The trade estimate for global ending stocks prior to the report was 276.8 mmt. Old crop ending stocks saw a slight reduction from June at 285 mmt to 284.2 mmt. The dollar is starting to inch higher again, but it is still nowhere close to where it was at the start of the year. The weaker dollar gives the U.S. a price advantage versus Brazil, which should continue to help exports. With the large number of shorts, trade deals could get corn moving higher again quickly as seen with the rumors of a Chinese purchase announcement ahead of the Independence Day weekend. If you like this article and would like to receive more information on the commodity markets, please use the link to join our email list Sign Up Now Please consider the following trade idea: Sell 2 puts for a 10 1/2 cent credit or collect $525/Trade Package and pay 12 1/2 cents or $625 for the $4.25 call. This trade costs you nothing to put on, you actually get a $525 credit/Trade Package to put on the trade. If Dec corn hits $3.84 or lower buy back the entire spread, capping downside at $1,075 per spread. The low for the year on the continuous contract is $3.85. Profit = 45 1/2 cents or $2,275/Trade Package with corn at $4.60 at expiration, Profit = 85 1/2 cents or $4,275/Trade Package with corn at $5.00 at expiration, Profit = 135 1/2 cents or $6,775/Trade Package with corn at $5.50 at expiration ALL PRICES ARE FRIDAY'S SETTLEMENT – DEC '25 CORN CLOSED @ 412 1/4 If you like this article and would like to receive more information on the commodity markets, please use the link to join our email list Sign Up Now If you're ready to start trading, click the link below to open an account with Walsh Trading, Inc. Open An Account Hans Schmit, Walsh Trading Direct 312-765-7311 Toll Free 800-993-5449 hschmit@ Walsh Trading, Inc. is registered as a Guaranteed Introducing Broker with the Commodity Futures Trading Commission and an NFA Member. Futures and options trading involves substantial risk and is not suitable for all investors. Therefore, individuals should carefully consider their financial condition in deciding whether to trade. Option traders should be aware that the exercise of a long option will result in a futures position. The valuation of futures and options may fluctuate, and as a result, clients may lose more than their original investment. The information contained on this site is the opinion of the writer or was obtained from sources cited within the commentary. The impact on market prices due to seasonal or market cycles and current news events may already be reflected in market prices. PAST PERFORMANCE IS NOT NECESSARILY INDICATIVE OF FUTURE RESULTS. All information, communications, publications, and reports, including this specific material, used and distributed by Walsh Trading, Inc. ('WTI') shall be construed as a solicitation for entering into a derivatives transaction. WTI does not distribute research reports, employ research analysts, or maintain a research department as defined in CFTC Regulation 1.71.
National Post
4 hours ago
- National Post
'I set the deal': Trump's authoritarian style raises alarms about future of U.S. democracy
Article content Article content Administration officials also pulled $175 million from the University of Pennsylvania in March over a dispute around women's sports. They restored it when school officials agreed to update records set by transgender swimmer Lia Thomas and change their policies. Article content Columbia University bent to Trump by putting its Middle East studies department under new supervision, among other changes, after the administration pulled $400 million in federal funding. At the University of Virginia, President James Ryan resigned under pressure following a Justice Department investigation into diversity, equity and inclusion practices. A similar investigation was opened Thursday at George Mason University. Article content 'Federal funding is a privilege, not a right, for colleges and universities,' said Kush Desai, a White House spokesman. Such steps were unheard of before Trump took office. Ted Mitchell, president of the American Council on Education and an Education Department official under President Barack Obama, said Trump isn't seeking deals but is 'demanding more and more and more.' Article content Article content 'Institutional autonomy is an important part of what makes higher education work,' he said. 'It's what enables universities to pursue the truth without political considerations.' Article content The Fed has also faced Trump's wrath. He blames Fed Chair Jerome Powell for moving too slowly to cut interest rates, which could make consumer debt like mortgages and auto loans more affordable. It could also help the U.S. government finance the federal debt that's expected to climb from the tax cuts that Trump recently signed into law. Article content Powell has held off on cutting the central bank's benchmark rate, as Trump's tariffs could possibly worsen inflation and lower rates could intensify that problem. Desai said the White House believes the Fed should act based on what the data currently shows, which is that 'President Trump's policies have swiftly tamed inflation.' Article content Although Trump has said he won't try to fire Powell — a step that might be impossible under the law anyway — he's called on him to resign. In addition, Trump's allies have increased their scrutiny of Powell's management, particularly an expensive renovation of the central bank's headquarters. Article content David Wessel, a senior fellow in economic studies at the Brookings Institution, said Trump's approach could undermine the Fed's credibility by casting a political shadow over its decisions. Article content 'There will be real costs if markets and global investors think the Fed has been beaten into submission by Trump,' he said. Article content Trump originally wanted to enact sweeping tariffs in April. In his view, import taxes would fix the challenge of the U.S. buying too much from other countries and not selling enough overseas. Article content After a backlash in financial markets, Trump instituted a three-month negotiating period on tariffs. Peter Navarro, one of his advisers, said the goal was '90 deals in 90 days.' Article content The administration announced a few trade frameworks with the United Kingdom and Vietnam, but Trump ran out of patience. He's sent letters to two dozen nations and the European Union informing them of their tariff rates, such as 30 per cent against the EU and Mexico, potentially undercutting the work of his own negotiators.
Globe and Mail
4 hours ago
- Globe and Mail
LASE Investors Have Opportunity to Join Laser Photonics Corporation Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Laser Photonics Corporation ('Laser Photonics' or 'the Company') (NASDAQ: LASE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Laser Photonics disclosed in a May 29, 2025, SEC filing that it had "received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC ('Nasdaq') stating that since it had not received the Company's Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024 (the 'Initial Delinquent Filing'), the Company does not comply with Nasdaq's Listing Rules for continued listing." The filing continued, "the Company has until June 16, 2025, to submit a plan to regain compliance with respect to these delinquent reports." Based on this news, shares of Laser Photonics fell by more than 6.5% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
